美国研究综述-Adobe、Braveheart Bio、CACI International

路透中文
Aug 31
美国研究综述-<a href="https://laohu8.com/S/ADBE">Adobe</a>、<a href="https://laohu8.com/S/BRVE">Braveheart Bio</a>、CACI International

路透8月31日 - 周一,华尔街证券分析师上调了包括Adobe、Braveheart Bio和CACI International在内的几家美国上市公司的评级和目标股价。

重点摘要

* Adobe Inc ADBE.O:杰富瑞将目标价从230美元上调至285美元

* Braveheart Bio, Inc. BRVE.O:杰富瑞首次覆盖该股,给予“买入”评级

* CACI International Inc CACI.N:TD Cowen将目标价从550美元上调至700美元

以下是路透周一报道的关于美国公司的研究动态摘要。股票条目按字母顺序排列。

* Adobe Inc ADBE.O:杰富瑞将目标价从230美元上调至285美元

* ATI Inc ATI.N:TD Cowen将目标价从210美元上调至250美元

* Braveheart Bio Inc BRVE.O:杰富瑞首次覆盖,给予“买入”评级

* Braveheart Bio Inc BRVE.O:杰富瑞(Jefferies)首次覆盖,目标价48美元

* BRC Inc BRCC.N:D.A. Davidson 将目标价从 2.5 美元上调至 25 美元,以反映 1 股换 10 股的股票反向拆分

* CACI International Inc CACI.N:TD Cowen将目标价从550美元上调至700美元

* Dollar Tree Inc DLTR.O:Piper Sandler将目标价从114美元上调至121美元

* 霍尼韦尔航空航天公司 HONA.O:TD Cowen将目标价从250美元下调至180美元

* 洲际交易所(Intercontinental Exchange Inc) ICE.N:杰富瑞(Jefferies)将目标价从171美元上调至189美元

* Protagonist Therapeutics Inc PTGX.O:杰富瑞将目标价从169美元上调至171美元

* Rubrik Inc RBRK.N:加拿大帝国商业银行(CIBC)将目标价从115美元上调至120美元

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10